CLAIMS:

1. Use of budiodarone or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of an extended episode of atrial fibrillation (AFib) in a patient with paroxysmal or persistent AFib, wherein the extended episode of AFib lasts at least 30 minutes.

2. The use of claim 1, wherein the medicament is adapted to be administered by oral, sublingual, intravenous, rectal, or aerosol administration.

3. The use of claim 2, wherein the medicament is adapted to be administered orally in the form of capsules, pills, or tablets.

4. The use of claim 3, wherein a unit dose of the medicament provides from about 400 mg to about 2,000 mg of the budiodarone or the pharmaceutically acceptable salt thereof.

5. The use of claim 4, wherein the unit dose of the medicament provides from about 800 mg to about 1,200 mg of the budiodarone or the pharmaceutically acceptable salt thereof.

6. The use of claim 5, wherein the unit dose of the medicament provides about 1,000 mg of the budiodarone or the pharmaceutically acceptable salt thereof.

7. The use of claim 5, wherein the unit dose of the medicament provides at least 900 mg of the budiodarone or the pharmaceutically acceptable salt thereof.

8. The use of claim 1, wherein the medicament further comprises a blood thinner, wherein the blood thinner is dabigatran, edoxaban, apixaban, or rivaroxaban.

9. The use of claim 1, wherein said budiodarone or the pharmaceutically acceptable salt thereof is budiodarone tartrate.

10. The use of claim 1, wherein a unit dose of the medicament provides at least about 900 mg of the budiodarone or the pharmaceutically acceptable salt thereof.

11. The use of claim 1, wherein a unit dose of the medicament provides an amount of the budiodarone or the pharmaceutically acceptable salt thereof sufficient to produce a plasma concentration of at least 13 ng/mL of the budiodarone or the pharmaceutically acceptable salt thereof for a period sufficient cardiovert the patient to normal sinus rhythm.

12. The use of claim 11, wherein the amount of the budiodarone or the pharmaceutically acceptable salt thereof is sufficient to produce a plasma concentration of the budiodarone or the pharmaceutically acceptable salt thereof of about 50 ng/mL to about 350 ng/mL for at least about 5 hours.

13. The use of claim 11, wherein the amount of the budiodarone or the pharmaceutically acceptable salt thereof is sufficient to produce a plasma concentration of about 50 ng/mL to about 350 ng/mL for at least about 6 hours.

14. The use of claim 11, wherein the amount of the budiodarone or the pharmaceutically acceptable salt thereof is sufficient to provide a plasma concentration of about 50 ng/mL to about 350 ng/mL for at least about 5 hours within about an hour of receiving the unit dose.

15. A kit of parts comprising a single dose of budiodarone or the pharmaceutically acceptable salt thereof in an amount effective in cardioverting a patient and instructions for post-administration monitoring of the patient.

16. The kit of parts of claim 15, wherein the single dose is a single oral unit dose comprising at least 900 mg budiodarone or the pharmaceutically acceptable salt thereof.